Brief: Phio Pharmaceuticals Announces FDA Clearance To Initiate Clinical Trial Of Ph-762 For Treatment Of Skin Carcinomas
16/05/2023 12:41
Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES FDA CLEARANCE TO INITIATE
CLINICAL TRIAL OF PH-762 FOR TREATMENT OF SKIN CARCINOMAS
* PHIO PHARMACEUTICALS - TO FOCUS EFFORTS ON U.S. CLINICAL
TRIAL
AND INTENDS TO WIND DOWN FIRST-IN-HUMAN CLINICAL TRIAL FOR
PH-762 IN FRANCE
* PHIO - TO INITIATE PHASE 1B CLINICAL TRIAL OF INTRATUMORAL
PH-762 IN PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA,
MELANOMA, MERKEL CELL IN H2
Source text for Eikon: ID:nPn8Mq1pBa
Further company coverage: PHIO.O
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing